Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 and SI-B003 in recurrent or metastatic cervical cancer and gynecological malignancies
NCT05990803Phase 2Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan, SI-B003 in Cervical Cancer (CC), gynecological malignancies, sponsored by Biokin Pharmaceutical. Started Nov 2023; status: recruiting.
02
Drugs
izalontamab brengitecanSI-B003
03
Conditions
Cervical Cancer (CC)gynecological malignancies
Beyond the preview
Go deeper on NCT05990803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05990803.